BioMark has recently completed a very encouraging metabolome study that has implication for biomarker signature related to cancer diagnosis. The discovery is being patented.
No paperwork, no hassle. We keep things digital, easy and regular.
*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.
BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung
BioMark’s Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost
Form 7 Monthly Progress Report April 2025 Name of Listed Issuer: Trading Symbol: Number of
Form 7 Monthly Progress Report April 2025 Name of Listed Issuer: Trading Symbol: Number of
BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test
1 604 370 0779
130 3851 Shell Road
Richmond BC
Canada V6X 2W2